2 Underrated Biotech Stocks to Buy Now
These two biotech companies are safe bargains in today's volatile market.
Why Moderna Is Less Risky Than You Think
Its coronavirus vaccine will likely be successful; its technology has huge potential; and the company has a healthy balance sheet.
Why You Shouldn't Ignore Johnson & Johnson
The storied pharmaceutical company remains one of the safest dividend-growth stocks in the market today.
Is Teladoc Health a Buy on the Pullback?
Secular headwinds in the digital health market, the company's improving sales mix, and its synergistic merger with Livongo all make it look like an attractive opportunity.
4 Reasons CVS Health Is a Promising Value Pick
CVS Health is trading at exceptionally low multiples, but it's been a net beneficiary of the pandemic -- not to mention its diversified business model and improving balance sheet.
Here's Why Gilead Sciences Is More Than Just a COVID-19 Play
Despite its robust HIV portfolio, promising COVID-19 therapeutic, and solid dividend yield, this stock is still a bargain today.
Why I Think Bristol Myers Squibb Is Too Cheap to Miss
This blue-chip pharma stock is a bargain for long-term investors.
This Medical Device Player Could Be a Top-Notch Pick in 2020
Abiomed is definitely not cheap, but there is significant upside left in this stock.
4 Reasons AbbVie Is More Attractive Than You Think
AbbVie could turn out to be a top-notch investment despite the upcoming expiration of its Humira patent.
Does This Pharma Company's Lead Asset Make it a Buy Today?
The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.
Is Pfizer the Best Way to Play the Coronavirus Vaccine Race?
Pfizer could very likely be the first company to secure emergency use authorization for its coronavirus vaccine candidate.